Cargando…

Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience

Debulking surgery followed by systemic chemotherapy—including three-weekly intravenous paclitaxel and carboplatin (GOG-158)—is the cornerstone for advanced epithelial ovarian, fallopian tubal, and peritoneal cancer (EOC) treatment. In this scenario, Federation of Gynecology and Obstetrics (FIGO) sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chia-Hua, Kuo, Hsiao-Li, Chen, Tzu-Chien, Weng, Chia-Sui, Lim, Ling, Huang, Wan-Chun, Chang, Chih-Long, Su, Tsung-Hsien, Wang, Kuo-Gon, Wang, Kung-Liahng, Yang, Yuh-Cheng, Chen, Jen-Ruei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277645/
https://www.ncbi.nlm.nih.gov/pubmed/32443497
http://dx.doi.org/10.3390/ijerph17103523
_version_ 1783543166725521408
author Chang, Chia-Hua
Kuo, Hsiao-Li
Chen, Tzu-Chien
Weng, Chia-Sui
Lim, Ling
Huang, Wan-Chun
Chang, Chih-Long
Su, Tsung-Hsien
Wang, Kuo-Gon
Wang, Kung-Liahng
Yang, Yuh-Cheng
Chen, Jen-Ruei
author_facet Chang, Chia-Hua
Kuo, Hsiao-Li
Chen, Tzu-Chien
Weng, Chia-Sui
Lim, Ling
Huang, Wan-Chun
Chang, Chih-Long
Su, Tsung-Hsien
Wang, Kuo-Gon
Wang, Kung-Liahng
Yang, Yuh-Cheng
Chen, Jen-Ruei
author_sort Chang, Chia-Hua
collection PubMed
description Debulking surgery followed by systemic chemotherapy—including three-weekly intravenous paclitaxel and carboplatin (GOG-158)—is the cornerstone for advanced epithelial ovarian, fallopian tubal, and peritoneal cancer (EOC) treatment. In this scenario, Federation of Gynecology and Obstetrics (FIGO) stage, cell types, completeness of surgery, lymph nodes (LN) status, adjuvant chemotherapy regimens, survival status, progression-free survival (PFS), and overall survival (OS) of 192 patients diagnosed as having stage IIIA1–IVB EOC over January 2008–December 2017 were analyzed retrospectively. Of them, 100 (52.1%) patients had been debulked optimally. Of all cases, 64.1% and 10.9% demonstrated serous and clear-cell carcinoma. Moreover, the FIGO stage, surgery completeness, and LN status affected recurrence/persistence and mortality (all p < 0.001). Clear cell carcinoma led to shorter survival than serous carcinoma (p = 0.002). Adjuvant chemotherapy regimens were divided into five main groups according to previous clinical trials. However, choice of chemotherapy failed to demonstrate significant differences in patient outcomes. Similar results were found in the sub-analysis of optimally debulked cases, except that intraperitoneal chemotherapy could reduce mortality risk when compared with GOG-158 (p = 0.042). Notably, retroperitoneal LN dissection in all cases or optimally debulked cases reduced risks of recurrence/persistence and mortality, and prolonged PFS and OS significantly (all p < 0.05). Without optimal debulking, LN dissection led to little improvement in outcomes. Various modified chemotherapy regimens did not prolong PFS and OS or reduce recurrence/persistence and mortality risks. LN dissection is strongly recommended to improve the completeness of surgery and patient outcome. Clear cell type has a poorer outcome than serous type, which requires more aggressive treatment and follow-up.
format Online
Article
Text
id pubmed-7277645
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72776452020-06-12 Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience Chang, Chia-Hua Kuo, Hsiao-Li Chen, Tzu-Chien Weng, Chia-Sui Lim, Ling Huang, Wan-Chun Chang, Chih-Long Su, Tsung-Hsien Wang, Kuo-Gon Wang, Kung-Liahng Yang, Yuh-Cheng Chen, Jen-Ruei Int J Environ Res Public Health Article Debulking surgery followed by systemic chemotherapy—including three-weekly intravenous paclitaxel and carboplatin (GOG-158)—is the cornerstone for advanced epithelial ovarian, fallopian tubal, and peritoneal cancer (EOC) treatment. In this scenario, Federation of Gynecology and Obstetrics (FIGO) stage, cell types, completeness of surgery, lymph nodes (LN) status, adjuvant chemotherapy regimens, survival status, progression-free survival (PFS), and overall survival (OS) of 192 patients diagnosed as having stage IIIA1–IVB EOC over January 2008–December 2017 were analyzed retrospectively. Of them, 100 (52.1%) patients had been debulked optimally. Of all cases, 64.1% and 10.9% demonstrated serous and clear-cell carcinoma. Moreover, the FIGO stage, surgery completeness, and LN status affected recurrence/persistence and mortality (all p < 0.001). Clear cell carcinoma led to shorter survival than serous carcinoma (p = 0.002). Adjuvant chemotherapy regimens were divided into five main groups according to previous clinical trials. However, choice of chemotherapy failed to demonstrate significant differences in patient outcomes. Similar results were found in the sub-analysis of optimally debulked cases, except that intraperitoneal chemotherapy could reduce mortality risk when compared with GOG-158 (p = 0.042). Notably, retroperitoneal LN dissection in all cases or optimally debulked cases reduced risks of recurrence/persistence and mortality, and prolonged PFS and OS significantly (all p < 0.05). Without optimal debulking, LN dissection led to little improvement in outcomes. Various modified chemotherapy regimens did not prolong PFS and OS or reduce recurrence/persistence and mortality risks. LN dissection is strongly recommended to improve the completeness of surgery and patient outcome. Clear cell type has a poorer outcome than serous type, which requires more aggressive treatment and follow-up. MDPI 2020-05-18 2020-05 /pmc/articles/PMC7277645/ /pubmed/32443497 http://dx.doi.org/10.3390/ijerph17103523 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chang, Chia-Hua
Kuo, Hsiao-Li
Chen, Tzu-Chien
Weng, Chia-Sui
Lim, Ling
Huang, Wan-Chun
Chang, Chih-Long
Su, Tsung-Hsien
Wang, Kuo-Gon
Wang, Kung-Liahng
Yang, Yuh-Cheng
Chen, Jen-Ruei
Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience
title Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience
title_full Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience
title_fullStr Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience
title_full_unstemmed Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience
title_short Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience
title_sort outcomes in advanced stage epithelial ovarian, fallopian tubal, and peritoneal cancer after primary surgery and adjuvant chemotherapies: a single-institute real-world experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277645/
https://www.ncbi.nlm.nih.gov/pubmed/32443497
http://dx.doi.org/10.3390/ijerph17103523
work_keys_str_mv AT changchiahua outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience
AT kuohsiaoli outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience
AT chentzuchien outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience
AT wengchiasui outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience
AT limling outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience
AT huangwanchun outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience
AT changchihlong outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience
AT sutsunghsien outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience
AT wangkuogon outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience
AT wangkungliahng outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience
AT yangyuhcheng outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience
AT chenjenruei outcomesinadvancedstageepithelialovarianfallopiantubalandperitonealcancerafterprimarysurgeryandadjuvantchemotherapiesasingleinstituterealworldexperience